Signal
FDA grants priority voucher for higher-dose Wegovy, speeding Novo Nordisk's approval
Novo Nordisk has secured FDA approval for a higher dose of its obesity drug Wegovy, benefiting from a rare priority review voucher that accelerated clearance to just 54 days.
rss
clinical_trialsfdaapprovalsdrug_development
Evidence trail (top sources)
top sources (3 domains)domains are deduped. counts indicate coverage, not truth.3 posts in this window
- FDA approves higher Wegovy dose via 4th priority voucherpharmaphorum · pharmaphorum.com
- Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its block...Fierce Pharma (All) · fiercepharma.com
- BioPharma Divebiopharmadive.com
All evidence
All posts (loaded window)